UCB SA (id:326 UCB)
189.40 EUR
Opening hours: 09:00 - 17:30 (Central European Standard Time: 12/24/2024 6:25:15 PM)
Exchange closed, opens in 14 hours 34 minutes
About UCB SA
Market Capitalization 34.52B
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
| Headquarters (address) |
AllEe de la Recherche, 60 Brussels 1070 Belgium |
| Phone | 32 2 559 99 99 |
| Website | https://www.ucb.com |
| Employees | 9K |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | UCB |
| Exchange | European Stock Exchange |
| Currency | EUR |
| 52 week range | 76.80 - 190.20 |
| Market Capitalization | 34.52B |
| Dividend yield forward | 2.92 % |
| Dividend yield forward Belgium (ID:14, base:74) | 18.03 % |
| P/E trailing | 149.14 |
| P/E forward | 26.52 |
| Price/Sale | 6.33 |
| Price/Book | 3.86 |
| Beta | 3.00 |
| EPS | 1.22 |
| EPS Belgium (ID:14, base:79) | 4.60 |
Dividend growth streak
UCB SA has raised their dividend 14.00 years in a row. This is above the 4.499729 year average in the 'Biotechnology' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: UCB SA has raised their dividend 2.92 years in a row. This is below the 42122.093500 year average in the 'Biotechnology' industry
Compound Average Growth Rate 3 Years
Compound Average Growth Rate 3 Years: UCB SA has raised their dividend 2.36 years in a row. This is below the 23.957000 year average in the 'Biotechnology' industry
Compound Average Growth Rate 5 Years
Compound Average Growth Rate 5 Years: UCB SA has raised their dividend 2.42 years in a row. This is below the 12.560500 year average in the 'Biotechnology' industry
Compound Average Growth Rate 10 Years
Compound Average Growth Rate 10 Years: UCB SA has raised their dividend 2.69 years in a row. This is below the 10.207200 year average in the 'Biotechnology' industry
Payout Ratio
Payout Ratio: UCB SA has raised their dividend 111.48 years in a row. This is below the 148.467900 year average in the 'Biotechnology' industry
Self funded year
UCB SA years needed to self fund. This is above the 34.112811 year average in the 'Biotechnology' industry
Dividend growth streak
UCB SA has raised their dividend 14.00 years in a row. This is above the 4.499729 year average in the 'Biotechnology' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: UCB SA has raised their dividend 2.92 years in a row. This is below the 42122.093500 year average in the 'Biotechnology' industry
Compound Average Growth Rate 3 Years
Compound Average Growth Rate 3 Years: UCB SA has raised their dividend 2.36 years in a row. This is below the 23.957000 year average in the 'Biotechnology' industry
Compound Average Growth Rate 5 Years
Compound Average Growth Rate 5 Years: UCB SA has raised their dividend 2.42 years in a row. This is below the 12.560500 year average in the 'Biotechnology' industry
Compound Average Growth Rate 10 Years
Compound Average Growth Rate 10 Years: UCB SA has raised their dividend 2.69 years in a row. This is below the 10.207200 year average in the 'Biotechnology' industry
Payout Ratio
Payout Ratio: UCB SA has raised their dividend 111.48 years in a row. This is below the 148.467900 year average in the 'Biotechnology' industry
Self funded year
UCB SA years needed to self fund. This is above the 34.112811 year average in the 'Biotechnology' industry